Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst ratings page for full changes and other stock views.
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Needham analyst Ami Fadia upgraded Biogen Inc.
(NASDAQ:BIIB) from Hold to Buy and announced a $255 price target.
Biogen shares closed at $195.34 on Friday.
Stifel sees Biogen stock rallying nearly 32% from here.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN),…
Analysts change outlook on top names. Check out ratings page for upgrades, downgrades, and initiations.
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on…
Wall Street analysts changed outlook on top names. For complete changes, see analyst ratings page. AFRM upgraded, LYB raised…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
